MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.

Journal of Cellular Biochemistry is a premier academic journal dedicated to advancing the field of biochemistry and cellular biology. Published by Wiley, this influential journal has a significant impact factor that underscores its relevance and authority within the scientific community. With its ISSN 0730-2312 and E-ISSN 1097-4644, the journal has been on the frontier of research since its inception in 1982, and is expected to continue publishing cutting-edge studies through 2024. As evidenced by its ranking in the 2023 Scopus Quartiles, it holds a rank of Q2 in Biochemistry and Q3 in both Cell and Molecular Biology, placing it among the top tiers of scientific journals in these disciplines. The Journal of Cellular Biochemistry serves as a vital resource for researchers, professionals, and students alike, providing a platform for the dissemination of innovative ideas and findings that shape our understanding of cellular processes and biochemical pathways. Though it does not currently offer Open Access options, its robust peer-review process ensures that each publication meets the highest academic standards, thus solidifying its esteemed position in the landscape of biochemical research.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

CELL BIOCHEMISTRY AND BIOPHYSICS is a distinguished journal published by HUMANA PRESS INC, focusing on critical advancements in the fields of biochemistry, biophysics, and cell biology. Since its establishment, the journal has provided a robust platform for the dissemination of cutting-edge research, covering diverse aspects of cellular biochemistry and the physical principles that underlie biological systems. With an emphasis on interdisciplinary studies, the journal aims to facilitate knowledge exchange among researchers, professionals, and students from various scientific backgrounds. As reflected in its 2023 category rankings, it holds a respectable position in Q3 for Biochemistry and Cell Biology, and Q2 for both Biophysics and Medicine (miscellaneous), indicating its significant contribution to these fields. Although it operates under a subscription model, the journal's commitment to maintaining high publication standards ensures that only impactful studies are shared with its audience. With a range of articles spanning theoretical insights to practical applications, CELL BIOCHEMISTRY AND BIOPHYSICS is an essential resource for those aiming to stay at the forefront of biochemical and biophysical research.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Current Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING is an esteemed journal published by Bentham Science Publishers Ltd, focusing on the rapidly evolving fields of combinatorial chemistry and high-throughput screening. With ISSN 1386-2073 and E-ISSN 1875-5402, this journal provides a critical platform for researchers, professionals, and students engaged in the development and application of novel methodologies aimed at drug discovery and organic chemistry. Since its inception in 1998, the journal has consistently contributed valuable insights, achieving a respectable 2023 Category Quartile Ranking of Q3 across relevant categories including Computer Science Applications, Drug Discovery, and Organic Chemistry. Although it does not currently provide open access options, its rigorous peer-review process and commitment to scientific excellence enhance its reputation in the academic community. Researchers can leverage this journal's findings to stay at the forefront of advancements in their fields, making it an essential resource for anyone dedicated to innovation in chemistry and related disciplines.

MOLECULAR AND CELLULAR PROBES, published by Academic Press Ltd - Elsevier Science Ltd, stands as a prominent journal at the intersection of cell and molecular biology. With an ISSN of 0890-8508 and an E-ISSN of 1096-1194, this journal has consistently contributed to the scientific discourse since its inception in 1987, converging its scholarly content through to 2024. As a member of Q3 in both Cell Biology and Molecular Biology categories, it provides a platform for innovative research and critical insights into cellular mechanisms, signaling pathways, and molecular interactions. Its Scopus rankings position it within the top half of its categories, fostering a vibrant academic community that supports the exploration and advancement of biochemistry, genetics, and molecular biology. Although it does not currently offer Open Access, the high-quality peer-reviewed articles published in MOLECULAR AND CELLULAR PROBES are invaluable resources for researchers, professionals, and students who seek to stay at the forefront of breakthroughs in these essential fields.

Expert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.